Improving the experience of healthy volunteers during early phase clinical trials
How ICON’s application of a volunteer-centric approach is significantly improving recruitment and retention rates of healthy participants in early phase studies.
Healthy volunteers are clinical research heroes – they are essential to early phase trials and are vital participants in developing important, life changing therapies – but volunteer recruitment and enrolment is a challenge across the industry. Failure to recruit subjects can cause significant impacts on study resources. Reorienting the approach to healthy volunteer recruitment and implementing a volunteer-centric strategy can yield more positive results throughout the recruitment funnel and improve both recruitment and retention rates for early phase clinical trials.
Sophisticated strategies lead to study efficiency
Sponsors need rapid, flexible recruitment solutions to ensure their early phase studies are properly enrolled with healthy volunteers to meet their start-up timelines and budgets. Enrolment can be a long process with multiple stages of screening often taking several weeks. Not everyone who applies will be eligible based on the specifics of inclusion and exclusion criteria and there are typically a number of dropouts before the trial even begins. With these losses in the process, only 5-6% of all applicants are dosed in a clinical trial.
Incorporating volunteer centricity as the frame for recruitment and retention strategy focuses on the volunteer’s experience at key interaction points, including marketing outreach, initial screening and onsite clinical evaluation. Maintaining positive volunteer experiences at these points helps steer more efficient processes, resulting in recruitment rate improvement, reduced dropout rates and database growth. These improvements ripple throughout the study as larger volunteer databases can facilitate faster enrolment and minimised dropout prevents schedule delays. Minimised dropout also avoids the high costs of additional recruitment efforts to replace volunteers lost later in the funnel.
Mapping the volunteer journey
Understanding the volunteer journey is crucial to ultimately improving healthy volunteer recruitment. Mapping the journey can afford more control over the recruitment process and provide concrete, actionable steps for improving the volunteer experience and retention rates.
The volunteer journey begins with the decision process and then moves to the screening, onboarding and participation stages. Sophisticated online marketing strategies help maximise impact during the decision journey and grow the volunteer database. The onboarding stage includes all interaction moments from registration until participation. Optimising the volunteer journey at this stage helps reduce dropout rates at the screening stage, thus avoiding study start-up delays. After onboarding, volunteers move through the clinical trial journey. The optimisation of the participation experience generates positive recommendations, which can be measured by the Net Promoter Score (NPS) which is provided by the volunteer at the end of the process. A positive overall experience is crucial for volunteer retention, encouraging repeat participation and promotion.
ICON has mapped the volunteer journey throughout the clinical trial process in order to identify key milestones and potential drop out points. During this process, we identified strategic touchpoints throughout the journey where improvements could enhance the volunteer experience. Extensive volunteer surveys and panels were conducted to ensure we accurately captured the volunteers’ experiences at each stage of the journey. Including volunteer feedback informs which touchpoints to prioritise and how to best address any associated issues. For example, time and distance traveling to the screening centre was a recurring theme in both the mapping and survey exercises.
Measuring the method
While mapping the volunteer journey provides additional control over the process, tracking and measuring the impact of a volunteer-centric approach also allows for tactical refinement. Capturing data like dropout and retention rates and NPS scores provides feedback on the impact of volunteer-centric strategies. For example, after implementing a strategic approach to volunteer centricity, the Dutch region’s Net Promoter Scores rose more than 40%, climbing from 17 in 2021 to 24 in 2022. In addition, dropout rates reduced and overall volunteer satisfaction scores improved from 6.5 to 8 on a scale of 1-10. This data can also allow for higher visibility of cost per volunteer acquisition and enhance resource forecasting and budgeting for future trials.
Case study: New medical screening centre in Utrecht facilitates easier access for trial volunteers
ICON’s early phase clinic in Groningen, the Netherlands is one of Europe’s largest phase 1 and 2 research centres, where we conduct over 60 studies per year. More than 40% of these are first-in-human trials requiring large numbers of healthy volunteers. The clinic's location in the northern part of the country was a barrier for volunteers who voiced the need for a more accessible screening location.
ICON has expanded the more centrally located screening centre in Utrecht in response to volunteer feedback, reducing the travel burden on volunteers from the Netherlands as well as Belgium and Germany. The integration of a well-equipped laboratory ensures that more studies can be fully executed within a more accessible location – volunteers can attend both pre-trial screening and ambulatory visits during the trial. The reduced travel burden resolves a hurdle in the healthy volunteer journey and their experience in the new centre will continue to be tracked and measured for continuous improvement. The Utrecht screening centre serves as a pilot program for improving volunteer recruitment rates. Future expansion of screening capacity at other locations in Europe is currently being considered.
Conclusion
Healthy volunteers are a critical part of early phase clinical research. Combining volunteer perspectives with the latest digital tools will result in higher enrolment and retention rates throughout the trial and encourage repeat participation in future research.
To learn more about ICON's approach to healthy volunteer recruitment, contact us.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel